The Molecular Mechanism of Action of Superactive Human Leptin Antagonist (SHLA) and Quadruple Leptin Mutein Lan-2 on Human Ovarian Epithelial Cell Lines

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 2016 Aug 3

PMID 27480179

Citations 7

Authors

Elzbieta Fiedor

Ewa Lucja Gregoraszczuk

Affiliations

Soon will be listed here.

Abstract

Introduction: A number of leptin receptor antagonists have been synthesised for therapeutic use, with pre-clinical tests suggesting their future use in anticancer therapy. To our knowledge, there are no data concerning the possible application of leptin receptor blockers in ovarian cancer.

Methods: In this study, we evaluated two leptin receptor antagonists: superactive human leptin antagonist (SHLA) and quadruple leptin mutein, Lan-2 (L39A/D40A/F41A/I42A), on cell proliferation (Alamar Blue test, BrdU assay), cell cycle gene (qPCR) and protein expression (Western blot) and cell signalling pathways (Western blot) in three different types of cell lines: OVCAR-3, CaOV-3 and HOSEpiC.

Results: Both receptor blockers had no effect on non-cancerous HOSEpiC cell line proliferation; however, both reversed the stimulatory effect of leptin on CaOV-3 cell line proliferation to control levels and to below control levels in OVCAR-3 cells. In metastatic carcinoma CaOV-3, both ObR antagonists had an inhibitory effect on the cdk2/cyclin D1 complex, while in serous carcinoma, OVCAR-3, they only had an effect on cdk2 and cdk4 protein expression. SHLA had an inhibitory effect on all investigated signalling pathways in OVCAR-3, while only on Stat3 in CaOV-3. Lan-2 had an inhibitory effect on Stat3 and ERK1/2 in CaOV-3, while in OVCAR-3 it only affected Akt protein phosphorylation.

Conclusion: Based on these results, we conclude that SHLA and Lan-2 are promising leptin receptor inhibitors which could be used to block leptin activity, eliminating its negative effects on activities related to carcinogenesis. However, the selection of a specific antagonist should be related to tumour type.

Citing Articles

Leptin-Activity Modulators and Their Potential Pharmaceutical Applications.

Greco M, De Santo M, Comande A, Belsito E, Ando S, Liguori A Biomolecules. 2021; 11(7).

PMID: 34356668 PMC: 8301849. DOI: 10.3390/biom11071045.

Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity.

Wu C, Sundararajan V, Sheu B, Huang R, Wei L Cancers (Basel). 2019; 12(1).

PMID: 31861720 PMC: 7017004. DOI: 10.3390/cancers12010024.

The influence of leptin on the process of carcinogenesis.

Modzelewska P, Chludzinska S, Lewko J, Reszec J Contemp Oncol (Pozn). 2019; 23(2):63-68.

PMID: 31316286 PMC: 6630388. DOI: 10.5114/wo.2019.85877.

Leptin-induced signaling pathways in cancer cell migration and invasion.

Ghasemi A, Saeidi J, Azimi-Nejad M, Hashemy S Cell Oncol (Dordr). 2019; 42(3):243-260.

PMID: 30877623 DOI: 10.1007/s13402-019-00428-0.

Linking obesity-induced leptin-signaling pathways to common endocrine-related cancers in women.

Nyasani E, Munir I, Perez M, Payne K, Khan S Endocrine. 2018; 63(1):3-17.

PMID: 30218381 DOI: 10.1007/s12020-018-1748-4.

References

Chen C, Chang Y, Liu C, Chang K, Guo I . Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1. Breast Cancer Res Treat. 2006; 98(2):121-32. DOI: 10.1007/s10549-005-9139-y. View

Somasundar P, Frankenberry K, Skinner H, Vedula G, McFadden D, Riggs D . Prostate cancer cell proliferation is influenced by leptin. J Surg Res. 2004; 118(1):71-82. DOI: 10.1016/j.jss.2004.01.017. View

Di Yorio M, Bilbao M, Pustovrh M, Prestifilippo J, Faletti A . Leptin modulates the expression of its receptors in the hypothalamic-pituitary-ovarian axis in a differential way. J Endocrinol. 2008; 198(2):355-66. DOI: 10.1677/JOE-07-0622. View

Catalano S, Leggio A, Barone I, De Marco R, Gelsomino L, Campana A . A novel leptin antagonist peptide inhibits breast cancer growth in vitro and in vivo. J Cell Mol Med. 2015; 19(5):1122-32. PMC: 4420614. DOI: 10.1111/jcmm.12517. View

Samuel-Mendelsohn S, Inbar M, Weiss-Messer E, Niv-Spector L, Gertler A, Barkey R . Leptin signaling and apoptotic effects in human prostate cancer cell lines. Prostate. 2011; 71(9):929-45. DOI: 10.1002/pros.21309. View

Silha J, Krsek M, Skrha J, Sucharda P, Nyomba B, Murphy L . Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003; 149(4):331-5. DOI: 10.1530/eje.0.1490331. View

Owecki M, Nikisch E, Miczke A, Pupek-Musialik D, Sowinski J . Leptin, soluble leptin receptors, free leptin index, and their relationship with insulin resistance and BMI: high normal BMI is the threshold for serum leptin increase in humans. Horm Metab Res. 2010; 42(8):585-9. DOI: 10.1055/s-0030-1253422. View

Masamha C, Benbrook D . Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res. 2009; 69(16):6565-72. DOI: 10.1158/0008-5472.CAN-09-0913. View

Otvos Jr L, Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A . Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur J Cancer. 2011; 47(10):1578-84. DOI: 10.1016/j.ejca.2011.01.018. View

10.

Suh D, Yoon M, Choi K, Kim J . Significance of E2F-1 overexpression in epithelial ovarian cancer. Int J Gynecol Cancer. 2007; 18(3):492-8. DOI: 10.1111/j.1525-1438.2007.01044.x. View

11.

Beccari S, Kovalszky I, Wade J, Otvos Jr L, Surmacz E . Designer peptide antagonist of the leptin receptor with peripheral antineoplastic activity. Peptides. 2013; 44:127-34. DOI: 10.1016/j.peptides.2013.03.027. View

12.

Chen C, Chang Y, Lan M, Breslin M . Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways. Int J Oncol. 2013; 42(3):1113-9. DOI: 10.3892/ijo.2013.1789. View

13.

Uddin S, Bu R, Ahmed M, Abubaker J, Al-Dayel F, Bavi P . Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer. 2009; 8:74. PMC: 2754986. DOI: 10.1186/1476-4598-8-74. View

14.

Choi J, Park S, Leung P, Choi K . Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J Clin Endocrinol Metab. 2004; 90(1):207-10. DOI: 10.1210/jc.2004-0297. View

15.

Catalano S, Giordano C, Rizza P, Gu G, Barone I, Bonofiglio D . Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation. J Cell Physiol. 2008; 218(3):490-500. DOI: 10.1002/jcp.21622. View

16.

Scolaro L, Parrino C, Coroniti R, Otvos Jr L, Surmacz E . Exploring leptin antagonism in ophthalmic cell models. PLoS One. 2013; 8(10):e76437. PMC: 3789671. DOI: 10.1371/journal.pone.0076437. View

17.

Olsen C, Green A, Whiteman D, Sadeghi S, Kolahdooz F, Webb P . Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer. 2007; 43(4):690-709. DOI: 10.1016/j.ejca.2006.11.010. View

18.

Ptak A, Kolaczkowska E, Gregoraszczuk E . Leptin stimulation of cell cycle and inhibition of apoptosis gene and protein expression in OVCAR-3 ovarian cancer cells. Endocrine. 2012; 43(2):394-403. PMC: 3593082. DOI: 10.1007/s12020-012-9788-7. View

19.

Zhang B, Cai F, Zhong X . An overview of biomarkers for the ovarian cancer diagnosis. Eur J Obstet Gynecol Reprod Biol. 2011; 158(2):119-23. DOI: 10.1016/j.ejogrb.2011.04.023. View

20.

Bain G, Collie-Duguid E, Murray G, Gilbert F, Denison A, McKiddie F . Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas. Br J Cancer. 2015; 113(11):1641. PMC: 4705900. DOI: 10.1038/bjc.2015.391. View